P700Serum levels of endothelin-1, matrix metalloproteinases- 2, - 9 and C- reactive protein in patients with mild and severe degree of arterial hypertension

Kostov, Krasimir; Dimitrova, A; Grigoryan, Armine V.; Tisheva, S.; Russeva, Adelaida L.; Atanasova, Milena; Gospodinov, Konstantin; Blazhev, Alexander

doi:10.1093/cvr/cvu098.123

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our study in patients with essential HTN showed significantly higher serum concentrations of ET-1 compared to normotensive controls ( Figure 1 ). Elevated ET-1 levels in patients with HTN are consistent with some previous clinical studies [ 24 , 25 , 26 , 27 , 28 , 29 ], as well as with our previous results, which showed that serum ET-1 concentrations were significantly elevated in patients with high BP [ 10 , 30 ]. Other authors have reported that the levels of ET-1 are normal in patients with essential HTN, but point out that the local levels of ET-1 in the vascular wall are elevated [ 18 , 31 , 32 ].…”

Section: Discussionsupporting

confidence: 92%

Circulating Levels of Endothelin-1 and Big Endothelin-1 in Patients with Essential Hypertension

Kostov

Blazhev

2021

Pathophysiology

View full text Add to dashboard Cite

The role of endothelin-1 (ET-1) in the pathogenesis of hypertension (HTN) is not clearly established. There is evidence that its circulating levels are elevated in some forms of experimental and human HTN, but this was not a consistent finding. Based on these controversial data, we tested serum levels of ET-1 and Big ET-1 (the precursor of ET-1) in patients with essential HTN, comparing the results with those of healthy normotensive controls. The levels of ET-1 and Big ET-1 were measured by ELISA. Our results in patients with essential HTN showed that the mean levels of ET-1 (5.01 ± 2.1 pg/mL) were significantly higher (F = 6.34, p = 0.0144) than the mean levels in the control group (3.2 ± 1.0 pg/mL). The levels of Big ET-1 in patients with essential HTN (0.377 ± 0.1 pmol/L) were similar to those in the control group (0.378 ± 0.07 pmol/L) and did not differ significantly (F = 0.00, p = 0.9531). These data suggest that ET-1, but not Big ET-1, may play an important role in the pathogenesis of primary HTN.

show abstract

Section: Discussionsupporting

confidence: 92%

Circulating Levels of Endothelin-1 and Big Endothelin-1 in Patients with Essential Hypertension

Kostov

Blazhev

2021

Pathophysiology

View full text Add to dashboard Cite

show abstract

“…Long-term effects of MMP-2 and MMP-9 in the vessel wall are counterbalanced by expression of TIMPs and their concentrations begin to decline [ 75 , 76 , 77 ], and may even be reduced in comparison to those of the control group. Reasons for this conclusion, given our data from a previous study which showed that the concentrations of MMP-9 in patients with mild, and especially with severe, hypertension are reduced significantly, compared to those of controls [ 78 ]. Similar results are reported by Zervoudaki et al, who observed a significant decrease of plasma levels of MMP-2 and MMP-9 in patients with essential hypertension in comparison with normotensive persons [ 28 ].…”

Section: Discussionmentioning

confidence: 99%

Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes

Kostov

Blazhev

Atanasova

et al. 2016

IJMS

View full text Add to dashboard Cite

Endothelin-1 (ET-1) is one of the most potent vasoconstrictors known to date. While its plasma or serum concentrations are elevated in some forms of experimental and human hypertension, this is not a consistent finding in all forms of hypertension. Matrix metalloproteinases -2 and -9 (MMP-2 and MMP-9), which degrade collagen type IV of the vascular basement membrane, are responsible for vascular remodeling, inflammation, and atherosclerotic complications, including in type 2 diabetes (T2D). In our study, we compared concentrations of ET-1, MMP-2, and MMP-9 in pre-hypertensive (PHTN) and hypertensive (HTN) T2D patients with those of healthy normotensive controls (N). ET-1, MMP-2, and MMP-9 were measured by ELISA. Concentrations of ET-1 in PHTN and N were very similar, while those in HTN were significantly higher. Concentrations of MMP-2 and MMP-9 in PHTN and HTN were also significantly higher compared to N. An interesting result in our study is that concentrations of MMP-2 and MMP-9 in HTN were lower compared to PHTN. In conclusion, we showed that increased production of ET-1 in patients with T2D can lead to long-lasting increases in blood pressure (BP) and clinical manifestation of hypertension. We also demonstrated that increased levels of MMP-2 and MMP-9 in pre-hypertensive and hypertensive patients with T2D mainly reflect the early vascular changes in extracellular matrix (ECM) turnover.

show abstract

P700Serum levels of endothelin-1, matrix metalloproteinases- 2, - 9 and C- reactive protein in patients with mild and severe degree of arterial hypertension

Cited by 2 publications

References 0 publications

Circulating Levels of Endothelin-1 and Big Endothelin-1 in Patients with Essential Hypertension

Circulating Levels of Endothelin-1 and Big Endothelin-1 in Patients with Essential Hypertension

Serum Concentrations of Endothelin-1 and Matrix Metalloproteinases-2, -9 in Pre-Hypertensive and Hypertensive Patients with Type 2 Diabetes

Contact Info

Product

Resources

About